Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… | Phase 1 | suspended | Jul 9, 2024 | Fred Hutchinson Cancer Center | Recruitment on hold with plans to open to accrual again soon. | Enrollment / accrual |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | N/A | terminated | May 24, 2021 | Institut Cancerologie de l'Ouest | lack of patient enrolment | Enrollment / accrual |
| NCT05065736 | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase… | Early Phase 1 | terminated | Oct 4, 2021 | Roberto Vargas | Funding unavailable | Funding |
| NCT05417581 | Mitochondrial Oxygraphy on Subcutaneous and Peri-visceral Adipose Tissue: Influence of…(OxMiTiAd) | N/A | terminated | Jun 14, 2022 | University Hospital, Clermont-Ferrand | Difficulty of recruitment for Groups 1 and 3 not allowing all recruitment to be carried out over a… | Enrollment / accrual |
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | Phase 2 | suspended | Oct 20, 2017 | Dana-Farber Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | Phase 2 | terminated | Jun 19, 2019 | Gregory Daniels | Lack of funding | Funding |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph… | Phase 2 | terminated | Jan 9, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04527549 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV… | Phase 2 | terminated | Aug 26, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… | Phase 2 | terminated | Aug 6, 2021 | Fred Hutchinson Cancer Center | The study was closed due to the end of funding. | Funding |
| NCT05028621 | Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman… | N/A | suspended | Aug 31, 2021 | Case Comprehensive Cancer Center | Working on changing study vendor | Other (stated, no rule matched) |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT06516926 | SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or… | Phase 2 | terminated | Jul 24, 2024 | Jiangsu HengRui Medicine Co., Ltd. | The adjustment of the sponsor's R\&D strategy. | Sponsor / business decision |
| NCT07165756 | "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the…(MaVie) | — | terminated | Sep 10, 2025 | Institut de Cancérologie de Lorraine | Principal Investigator's departure | Investigator |
| NCT00799110 | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With… | Phase 2 | terminated | Nov 27, 2008 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT03503071 | Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy | — | withdrawn | Apr 19, 2018 | Kyungpook National University Hospital | protocol change | Other (stated, no rule matched) |
| NCT04539366 | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children,… | Phase 1 | suspended | Sep 7, 2020 | National Cancer Institute (NCI) | Other - review of safety data | Safety / toxicity |
| NCT04810871 | Surgical Resection of Latent Brain Tumors Prior to Recurrence | N/A | suspended | Mar 23, 2021 | Mayo Clinic | internal procedural reasons | Other (stated, no rule matched) |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years… | Phase 2 | withdrawn | Apr 1, 2025 | Memorial Sloan Kettering Cancer Center | Lack of funding | Funding |
| NCT02698293 | PDT Plus Vitamin D3 for Anal Dysplasia | Phase 1 | withdrawn | Mar 3, 2016 | Abramson Cancer Center at Penn Medicine | Covid-19 | COVID-19 / pandemic |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT05995236 | Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy | — | terminated | Aug 16, 2023 | Methodist Health System | So far, we have not been able to collect meaningful data for these patients which also led to our… | Other (stated, no rule matched) |
| NCT07075627 | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic… | — | withdrawn | Jul 20, 2025 | Addario Lung Cancer Medical Institute | Sponsor/Funder decision | Other (stated, no rule matched) |
| NCT02962661 | Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients… | Phase 1 | suspended | Nov 11, 2016 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | terminated | May 15, 2017 | Wake Forest University Health Sciences | PIs not interested in continuing with the trial. | Other (stated, no rule matched) |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally… | Phase 1 / Phase 2 | terminated | Sep 13, 2017 | Hoffmann-La Roche | The study was closed because the sponsor decided not to continue the development of certain… | Sponsor / business decision |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT03529565 | Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the… | — | terminated | May 18, 2018 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT03662074 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small… | Phase 2 | terminated | Sep 7, 2018 | Wake Forest University Health Sciences | After interim analysis decided not to move forward with continuing the trial. | Efficacy / futility |
| NCT03843359 | A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With… | Phase 1 | terminated | Feb 18, 2019 | GlaxoSmithKline | Business Decision | Sponsor / business decision |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma(JAZZ) | Phase 2 | terminated | Mar 11, 2019 | Wake Forest University Health Sciences | Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this… | Other (stated, no rule matched) |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… | Phase 1 / Phase 2 | terminated | Mar 11, 2019 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing… | N/A | suspended | Nov 30, 2020 | Roswell Park Cancer Institute | Protocol being updates and staff trained | Other (stated, no rule matched) |
| NCT06124118 | Tumor Treating Fields for Locally Advanced NSCLC(NOVOCURE) | Phase 1 | withdrawn | Nov 9, 2023 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | withdrawn | Jan 24, 2024 | Fudan University | The study was withdrawn before participant enrollment because the research team decided not to… | Enrollment / accrual |
| NCT07234799 | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic… | N/A | suspended | Nov 18, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase… | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Michael McHale | Due to loss of funding | Funding |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer… | Early Phase 1 | terminated | Jan 8, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to… | Phase 1 | suspended | Jan 6, 2023 | National Cancer Institute (NCI) | Other - DLT assessment and phase 2 dose determination | Other (stated, no rule matched) |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… | Phase 1 / Phase 2 | suspended | Jan 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | Phase 4 | withdrawn | Mar 4, 2024 | PharmaEssentia | In alignment with company strategic direction. | Sponsor / business decision |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced… | Phase 2 | suspended | Jul 9, 2025 | Hebei Medical University Fourth Hospital | Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug… | Drug supply |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | Phase 1 / Phase 2 | suspended | Jan 30, 2026 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03068403 | Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After…(RECT) | N/A | terminated | Mar 1, 2017 | University Hospital, Bordeaux | target number of inclusion not reached | Other (stated, no rule matched) |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute… | Phase 2 | terminated | Apr 4, 2018 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT04119453 | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent… | Phase 2 | terminated | Oct 8, 2019 | Elevar Therapeutics | The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development… | Other (stated, no rule matched) |
| NCT05307874 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors(EVICTION-2) | Phase 1 / Phase 2 | terminated | Apr 1, 2022 | ImCheck Therapeutics, an Ipsen company | The study was terminated based on sponsor decision unrelated to safety or efficacy. The study met… | Safety / toxicity |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in…(AIPAC-003) | Phase 2 / Phase 3 | terminated | Feb 28, 2023 | Immutep S.A.S. | Sponsor Decision | Sponsor / business decision |
| NCT06021600 | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to… | Phase 1 | terminated | Sep 1, 2023 | M.D. Anderson Cancer Center | Slow participant enrollment | Enrollment / accrual |
| NCT06472726 | Mental Health App for Cancer Survivors Study(MACS) | N/A | terminated | Jun 25, 2024 | University of Wisconsin, Madison | App developer is no longer in business | Sponsor / business decision |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | Phase 3 | terminated | Jan 26, 2017 | Canadian Urologic Oncology Group | Manufacturer discontinued the production of study drugs. | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials